Skip to content
Clinical Trials – home
Therapeutic area

Skin and subcutaneous tissue disorders – page 53

  • 844 clinical trials
  • 268 recruiting
  • 353 conditions
  • 25 countries

Conditions in this area

353 conditions with trials, the busiest first

Clinical trials in Skin and subcutaneous tissue disorders

844 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

844 clinical trials

Long-Term Safety Study of Everolimus for Patients with Tuberous Sclerosis Complex and Refractory Seizures

Registered drugNo placebo
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years
  • Substances:Everolimus
  • Sponsor:Novartis Pharma AG

Diabetes mellitus+1

Not recruiting

Study on the Effectiveness of Oxygen Therapy for Patients with Diabetic Foot Ulcers

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Oxygen
  • Sponsor:Amsterdam UMC Stichting

Skin cancer

Not recruiting

Study of L19IL2 and L19TNF for Patients with Skin Cancer Suitable for Direct Tumor Injection

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bifikafusp Alfa
  • Sponsor:Philogen S.p.A.

Study on Canakinumab for Patients with PAPA Syndrome

Registered drug
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Canakinumab
  • Sponsor:IRCCS Istituto Giannina Gaslini

Study of Cemiplimab Alone and with RP1 for Patients with Advanced Skin Squamous Cell Carcinoma

Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:Replimune Group Inc.

Renal cell carcinoma+2

Not recruiting

Study on Patient Preference for Subcutaneous Pembrolizumab with Hyaluronidase vs. Intravenous Pembrolizumab in Melanoma, Renal Cell Carcinoma, and Lung Cancer Patients

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Study of RO7247669 at Different Doses for People with Previously Untreated Advanced Melanoma that Cannot be Removed by Surgery or Has Spread

InvestigationalNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Ro7247669
  • Sponsor:F. Hoffmann-La Roche AG

Dermatitis atopic

Not recruiting

Study on Tralokinumab for Moderate-to-Severe Atopic Hand Eczema in Patients Needing Systemic Therapy

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Tralokinumab
  • Sponsor:Leo Pharma A/S

Study on Binimetinib, Encorafenib, and Pembrolizumab for Patients with BRAF V600 Mutation-Positive Melanoma and Brain Metastasis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Binimetinib
  • Sponsor:Unicancer

Pemphigoid

Not recruiting

Study on Efgartigimod Alfa and Prednisone for Adults with Bullous Pemphigoid

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx

Study of Nivolumab and Relatlimab for Patients with Stage III-IV Melanoma After Surgery

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Bristol Myers Squibb International Corporation

Study on the Effectiveness and Safety of Remibrutinib Compared to Placebo and Omalizumab in Adults with Chronic Spontaneous Urticaria Uncontrolled by Antihistamines

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Omalizumab
  • Sponsor:Novartis Pharma AG

Substances studied in this area

The therapies tested most often in Skin and subcutaneous tissue disorders trials.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.